News

Disclosure notice in Eurocine Vaccines

Eurocine Vaccines AB hereby announces that Flerie Invest AB has acquired shares in the company and now holds more than 15 % of the shares.…

Flaggningsmeddelande i Eurocine Vaccines

Eurocine Vaccines AB meddelar härmed att Flerie Invest AB har förvärvat aktier i bolaget och passerat flaggningsgränsen om 15 % av röster och kapital. Flerie…

Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate

Expanding its portfolio, Eurocine Vaccines adds considerable value by the new HSV-2 vaccine candidate, which holds significant market potential. Currently, Herpes Simplex Virus Type 2,…

Calendar

BIO-Europe

BIO-Europe has grown into Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain have come togetherRead…

Biotechgate Digital Partnering

Eurocine Vaccines, a dedicated and returning participant, will join the Biotechgate Digital Partnering to meet with people in the vaccine area, both new connections and already establishedRead…